Biotech Firm Terminates Lease At BXP's Waltham Campus

Boston Properties' 1100 Winter St. in Waltham.
Boston Properties' 1100 Winter St. In Waltham

After laying off the majority of its staff, a biotech company has reached an agreement to terminate a lease for its U.S. headquarters in Waltham.

AlloVir, a company specializing in cell therapy research and development, agreed to pay $7M to terminate its 78K SF lease at 1100 Winter St. in Waltham, according to a Securities and Exchange Commission disclosure filed earlier this month.

Landlord BXP, which previously traded as Boston Properties, agreed to terminate the lease, which was supposed to run through July 31, 2028, Banker & Tradesman first reported.

AlloVir also terminated a sublease with AMAG Pharmaceuticals for a portion of its space in the building that AlloVir had agreed to occupy in 2021, according to SEC filings.

The termination comes after AlloVir laid off 95% of its staff in December and halted three drug trials, Fierce Biotech reported.

BXP declined to comment on the termination. AlloVir and AMAG didn't respond to Bisnow's requests for comment.

The building is part of the 957K SF Bay Colony campus that BXP acquired in 2011, according to the REIT's website. The campus has four buildings on 58 acres adjacent to the Cambridge Reservoir.

In October, construction firm DPR Construction expanded its operations to a new 200-person office at another building on the campus, 950 Winter St. Other tenants on the campus include Verizon Connect, United Health Group, GlaxoSmithKline and Matrix Capital Management Co.

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's Boston Newsletters
Related Stories

Energy Company Opens 125K SF Newton Office: The Boston Deal Sheet

Simon Approaching End Of The Road With Struggling Suburban Boston Mall

Wu Proposes Tax Breaks To Jump-Start Stalled Housing Projects

Taconic Partners Sheds Another NYC Life Sciences Property

Judge Dismisses Suit Alleging Alexandria Misled Investors Over Portfolio Strength

Oxford Properties' U.S. Investment Head On Why It's Buying Office Again — And Where

New Occupiers And More VC Money Fuel UK Life Sciences Rebirth

DFW's Life Sciences Sector Offers Startups The Ingredients They Need To Scale

Davis Looks To Sell 16-Building Beacon Hill, Back Bay Portfolio

Healey's New Data Center Rules Make Massachusetts A Tough Sell For Developers

Anthropic Doubling Local Presence With Cambridge Office Lease

Berkeley Partners Buys 2 Industrial Buildings For $36M: The Boston Deal Sheet